Consideraciones para pacientes con enfermedades cardiovasculares durante la pandemia de la COVID-19

Emilio Alfonso Rodríguez, Lorenzo Daniel Llerena Rojas, Lidia Maria Rodriguez Nande

Texto completo:



La enfermedad infecciosa causada por el nuevo coronavirus-2019 (COVID-19), produce un síndrome respiratorio agudo con implicaciones significativas en el sistema cardiovascular tanto en los pacientes con enfermedad cardiovascular preexistente (ECV), que poseen un riesgo de empeoramiento de su enfermedad y muerte, como en los que la infección se ha asociado con múltiples complicaciones directas e indirectas cardiovasculares. Las complicaciones cardiovasculares asociadas con más frecuencia a esta entidad incluyen lesión aguda del miocardio, miocarditis, síndromes coronarios agudos, arritmias y tromboembolismo venoso. Por otra parte, las terapias empleadas para el tratamiento de la enfermedad por COVID-19 pueden tener interacciones medicamentosas con los fármacos cardiovasculares ensombreciendo el pronóstico de los pacientes. El artículo resalta las distintas recomendaciones expuestas por expertos en la literatura médica respecto a las complicaciones cardiovasculares relacionadas con el nuevo coronavirus (COVID-19). 

Palabras clave

coronavirus, terapia cardiovascular, terapia COVID-19


Huang C, Wang Y, Li X, Lili R, Jianping Z, Yi H, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. Available from:

World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 Marzo 2020. Disponible en : ( consultado 08 de abril del 2020). 3. 1. Driggin E, Madhavan M V, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al.

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol [Internet]. 2020 May 12;75(18):2352 LP – 2371. Available from: 10.1016/j.jacc.2020.03.031

Biondi Zoccai G, Landoni G, Carnevale R, Cavarretta E, Sciarretta R, Frati G. SARSCoV-2 amd COVID-19: facing the pandemic together as citizens and cardiovascular practitioners. Minerva Cardioangiol 2020;68:61-4. Available from: 10.23736/S0026-4725.20.05250-0

Li B, Yang J, Zhao F et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol 2020. May;109(5):531-538. Available from: http://10.1007/s00392-020-01626-9

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. NatRev Cardiol 2020. May;17(5):259-260. Available from: http://10.1038/s41569-020-0360- 5

Zhou F, Yu T, Du R, Guohui F, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020. Mar 28;395(10229):1054-1062. Available from: http://10.1016/S0140-6736(20)30566-3 .

Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, et al. Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol 2016;24:490-502. Available from:

Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020. Mar;579(7798):270-273. Available from: http://10.1038/s41586-020-2012-7

Ge X-Y, Li J-L, Yang X-L, Chmura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013;503:535-8.

Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 2008;18:290-301. Available from:

Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med [Internet]. 2020;46(4):586–90. Available from:

World Health Organization. Coronavirus Disease 2019 (COVID-19). Disponible en : ( consultado 24 de abril del 2020).

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239- 1242. Available from: http://10.1001/jama.2020.2648

Marta Albalate, Arribas E, Torres M. Cintra R, Alcázar M, Puerta M, et al. Alta prevalencia de covid19 asintomático en hemodiálisis. Aprendiendo día a día el primer mes de pandemia de covid19. Disponible en: (consultado 06 de junio del 2020).

Li LQ, Huang T, Wang YQ, Zheng-ping W, Yuan L, Tao-bi H, et al. 2019 novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of metaanalysis. J Med Virol 2020. Mar 12. Available from: http://10.1002/jmv.25757

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. Feb 7. Available from: http://10.1001/jama.2020.1585.

Murthy S, Gomersall CD, Fowler RA. Care for Critically Ill Patients With COVID-19. JAMA [Internet]. 2020 Apr 21;323(15):1499–500. Available from:

Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-513.

Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) [Internet]. 2020;133(9). Available from: http://10.1097/CM9.0000000000000744

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Published online March 13, 2020. Available from:

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [Internet]. 2020 Feb 28;382(18):1708– 20. Available from:

Zidar DA, Al-Kindi SG, Liu Y, Krieger NI, Perzynski AT, Osnard M, et al. Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population. JAMA Netw Open [Internet]. 2019 Dec 2;2(12):e1916526–e1916526. Available from:

Kwong JC, Schwartz KL, Campitelli MA. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med [Internet]. 2018 Jun 27;378(26):2538–41. Available from:

Davis MM, Taubert K, Benin AL. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol 2006;48:1498-502.

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med [Internet]. 2020;46(5):846–8. Available from:

Sarkisian L, Saaby L, Poulsen TS. Clinical Characteristics and Outcomes of Patients with Myocardial Infarction, Myocardial Injury, and Nonelevated Troponins. Am J Med 2016;129:446 e5-446 e21.

Thygesen K, Alpert JS, Jaffe AS. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018;72:2231-64.

Yang X, Yu Y, Xu J. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020. Feb 24. pii: S2213-2600(20)30079-5. Available from: http://10.1016/S2213-2600(20)30079-5

Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis 2020. Mar 10. pii: S0033-0620(20)30055-4. Available from: http://10.1016/j.pcad.2020.03.001

Thygesen K, Alpert JS, Jaffe AS. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol 2018;72:2231-64.

Xu Z, Shi L, Wang Y. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020. Apr;8(4):420-22. Available from: http://10.1016/S2213-2600(20)30076-X

Liu Y, Yang Y, Zhang C. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63:364-374.

Behnood B, Mahesh V, David J, Taylor Ch, Isaac Dreyfus, Elissa D, et al.COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. Journal of the American College of Cardiology.Volume 75, Issue 23, June 2020.DOI: 10.1016/j.jacc.2020.04.031.

Wood S. TCT the Heat Beat: COVID-19 and the Heart: Insights from the Front Line 12 Marzo 2020. Disponible en: (Consultado 10, Abril 2020).

Frederick G.P. Welt, MD, Pinak B. Shah, MD, Herbert D. Aronow, MD, et al.Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC’s Interventional Council and SCAI. Journal of the American College of Cardiology. S0735-1097(20)34566-6.

Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med [Internet]. 2020;46(6):1111–3. Available from:

Buzon J, Roignot O, Lemoine S. Takotsubo Cardiomyopathy Triggered by Influenza A Virus. Intern Med 2015;54:2017-9.

Zompatori M, Ciccarese F, Fasano L. Overview of current lung imaging in acute respiratory distress syndrome. Eur Respir Rev 2014;23:519-30.

Ferguson ND, Fan E, Camporota L. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med 2012;38:1573-82. 41. Fan BE, Chong VCL, Chan SSW, Lim GH, Lim KGE, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol [Internet]. 2020 Jun 1;95(6):E131–4. Available from:

Tang N, Li D, Wang X, Sun Z. Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020 Apr;18(4):844-847. Available from: http://10.1111/jth.14768

Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020;248:117477.

KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product Insert. AbbVie Inc. (per FDA), North Chicago, IL, 2013. Disponible en: &dq=KALETRA(R)+oral+film+coated+tablets,+oral+solution,+lopinavir+ritonavir+oral+ film+coated+tablets,+oral+solution.+Product+Insert.+AbbVie+Inc.+(per+FDA),+North+ Chicago,+IL,+2013.+66.+34.+&ots=A4xd8b9QG9&sig=yPH3vqbA74Tv69vJ7GjsiDj8CI o&redir_esc=y#v=onepage&q&f=false . (Consultado 10 Abril del 2020).

DeCarolis DD, Westanmo AD, Chen YC, Boese AL, Walquist MA, Rector TS. Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin. Ann Pharmacother 2016;50:909-917.

Product monograph. Brilinta (ticagrelor). Mississauga, Ontario, Canada: AstraZeneca Canada Inc., May 2011. Disponible en: (Consultado 10 Abril del 2020).

Itkonen MK, Tornio A, Lapatto-Reiniluoto O et al. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther 2019;105:219-228.

Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020. Mar 16;14(1):72-73. Available from: http://10.5582/bst.2020.01047

Tonnesmann E, Kandolf R, Lewalter T. Chloroquine cardiomyopathy - a review of the literature. Immunopharmacol Immunotoxicol 2013;35:434-42.

Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.Drug Dev Res [Internet]. 2020 Mar 4;n/a(n/a). Available from:

Licencia de Creative Commons
Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.